Prosetin gets ODD designation

Status
Not open for further replies.

lgelb

Moderator
Forum Supporter
Joined
Nov 5, 2009
Messages
14,210
Reason
Lost a loved one
Diagnosis
00/0000
Country
US
State
WA
City
Seattle
Project ALS announced today that the Food and Drug Administration (FDA) has granted orphan drug designation to prosetin for the treatment of ALS. Prosetin is an oral, brain penetrant MAP4 kinase inhibitor developed by scientists at Columbia University for the treatment of ALS. Project ALS funded prosetin’s preclinical development and is sponsoring its translational and potential clinical development.
 
Status
Not open for further replies.
Back
Top